Merrimack Pharmaceuticals Inc (MACK)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard Peters
Employees:
27
ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA 02139
617-441-1000

Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its offers its first commercial product, Onivyde, which is a novel encapsulation of the marketed chemotherapy drug irinotecan in liposomal formulation. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 56.457 Million Shares Outstanding13.41 Million Avg 30-day Volume 11.451 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.06
Price to Revenue0.0 Debt to Equity0.0 EBITDA-4.66 Million
Price to Book Value5.3447 Operating Margin0.0 Enterprise Value70.326 Million
Current Ratio23.757 EPS Growth0.4 Quick Ratio20.307
1 Yr BETA 1.3055 52-week High/Low 9.45 / 3.76 Profit Margin0.0
Operating Cash Flow Growth78.3291 Altman Z-Score27.7232 Free Cash Flow to Firm -4.975 Million
View SEC Filings from MACK instead.

View recent insider trading info

Funds Holding MACK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MACK BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CROCKER GARY L SEE REMARKS

  • Officer
  • Director
8,000 2021-06-10 11

RAY RUSSELL T

  • Director
7,000 2021-06-10 1

NIELSEN ULRIK B.

  • Director
7,000 2021-06-10 1

ANDERSEN ERIC

WESTERN STANDARD LLC

WESTERN STANDARD PARTNERS LP

WESTERN STANDARD PARTNERS QP, L.P.

  • Director
  • SEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
1,269,648 2021-04-14 4

LEVY NOAH G.

NEWTYN MANAGEMENT, LLC

NEWTYN PARTNERS, LP

NEWTYN TE PARTNERS, LP

NEWTYN CAPITAL PARTNERS, LP

LEDO CAPITAL, LLC

  • Director
  • SEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
1,548,883 2020-12-01 1

22NW GP, INC.

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
1,241,896 2019-07-24 0

ARYEH JASON

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
3,802 2019-07-16 0

JFL CAPITAL MANAGEMENT, LLC

JFL CAPITAL MANAGEMENT LP

JFL CAPITAL HOLDINGS LLC

JFL PARTNERS FUND LP

LAWLER JOSEPH F.

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
3,705,629 2019-06-28 0

PETERS RICHARD PRESIDENT AND CEO

  • Officer
  • Director
0 2019-05-08 0

22NW, LP

22NW FUND, LP

22NW FUND GP, LLC

ENGLISH ARON R.

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
1,241,896 2019-04-15 0

LIN KENNETH

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
5,000 2019-03-13 0

FRANCHI JEAN M. CHIEF FINANCIAL OFFICER

  • Officer
0 2018-12-11 0

DRUMMOND DARYL C HEAD OF RESEARCH

  • Officer
0 2018-12-11 0

MUNSIE JEFFREY A GENERAL COUNSEL

  • Officer
0 2018-12-11 0

SANTILLANA SERGIO L. CHIEF MEDICAL OFFICER

  • Officer
0 2018-12-11 0

QUIGLEY JAMES H.

  • Director
0 2018-06-13 0

DEMETRI GEORGE

  • Director
0 2018-06-13 0

DINEEN JOHN M.

  • Director
0 2018-06-13 0

PORTER MICHAEL E

  • Director
0 2017-09-13 0

MENDELSOHN JOHN

  • Director
0 2017-09-13 0

LEE VIVIAN S

  • Director
0 2017-09-13 0

NEEDHAM THOMAS E. JR. CHIEF BUSINESS OFFICER

  • Officer
0 2017-08-01 0

GREEN JOHN L. PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2017-06-14 0

STEWART EDWARD J. HEAD OF COMMERCIAL

  • Officer
51,385 2016-07-26 0

SCHOEBERL BIRGIT M. HEAD OF DISCOVERY

  • Officer
65,657 2016-07-25 0

MCCLEMENTS WILLIAM M. HEAD OF CORPORATE OPERATIONS

  • Officer
14,072 2016-02-29 0

SULLIVAN WILLIAM A. PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2016-02-08 0

MULROY ROBERT J. PRESIDENT AND CEO

  • Officer
  • Director
0 2016-02-08 0

LAIVINS PETER N HEAD OF DEVELOPMENT

  • Officer
0 2016-02-08 0

AL-WAKEEL YASIR B. CFO AND HEAD OF CORP DEV

  • Officer
0 2016-02-08 0

FEHR GORDON J.

  • Director
0 2015-05-13 0

SINSKEY ANTHONY J

  • Director
422,543 2014-12-18 0

DRESSER JAMES VAN B.

  • Director
168,974 2014-06-02 0

NASH SARAH E

  • Director
0 2014-05-13 0

KHAN FAZAL R. SVP OF MANUFACTURING

  • Officer
0 2014-02-11 0

NIYIKIZA CLET M. EVP OF DEVELOPMENT

  • Officer
0 2013-03-12 0

LOVENBERG WALTER M PHD

  • Director
84,033 2012-04-25 0

GAY ROBERT C

  • Director
954,519 2012-04-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 22:15:03 UTC -1.3764 1.4464 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 21:45:03 UTC -1.3764 1.4464 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 21:15:03 UTC -1.3764 1.4464 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 20:45:03 UTC -1.0637 1.1337 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 20:15:03 UTC -1.0637 1.1337 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 19:45:04 UTC -1.0637 1.1337 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 19:15:03 UTC -1.0637 1.1337 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 18:45:04 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 18:15:04 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 17:45:03 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 17:15:03 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 16:45:03 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 16:15:03 UTC -0.3543 0.4243 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 15:45:03 UTC -0.3577 0.4277 950000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 15:15:02 UTC -0.3577 0.4277 750000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 14:45:03 UTC -0.3577 0.4277 750000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 14:15:03 UTC -0.3577 0.4277 750000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 13:45:04 UTC -0.3577 0.4277 750000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 13:15:03 UTC -0.3577 0.4277 750000
MERRIMACK PHARMACEUTICALS IN MACK 2021-11-26 12:45:04 UTC -0.3577 0.4277 750000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments